Par Drugs and (Small Cap) Share Target 2026, 2027 To 2035
|
Par Drugs and Chemicals Limited |
|||
|
Price: ₹93.40 (7.75%) | ||
| 52 Week Low: ₹78.05 52 Week High: ₹122.43 |
|||
| Market Capital: 135.57 Crore (Small-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Par Drugs and Share Price Target For 2026
- 1.1.1: Par Drugs and Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Par Drugs and Share Price Target For 2027
- 1.2.1: Par Drugs and Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Par Drugs and Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Par Drugs and Brief Company Overview
- 4: Par Drugs and Financial Performance
- 4.0.1: Is Par Drugs and A Good Buy For Long Term?
Par Drugs and, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 26.6% returns in 5-year showing 4.7% quarterly revenue growth with 14.6% profit margin.
To predict the Par Drugs and's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Par Drugs and Share Price Target For 2026
The line chart displays the monthly closing prices of Par Drugs and with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Par Drugs and shares in 2026, see the table below.
Par Drugs and Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 103.65 (+10.97%) | Volatility: ATR T1 |
| 2026 Target 2 | 95.53 (+2.28%) | Trend: SMA200 |
| 2026 Target 1 | 95.04 (+1.75%) | Trend: Supertrend Resistance |
| Current Price | 93.40 | Par Drugs and's share price as of 15 Jun 2026 |
| Stop Loss 1 | 89.74 (-3.92%) | Trend: SMA50 |
| Stop Loss 2 | 88.39 (-5.37%) | Trend: EMA9 |
| Stop Loss 3 | 83.15 (-10.98%) | Volatility: ATR S1 |
Short-Term Technical Outlook
Current Technical Position: Par Drugs and is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹89.89 serves as the nearest technical reference point.
Historical Returns: 3-month: +7.59% | 6-month: -7.96% | 1-year: -11.42%
Par Drugs and Share Price Target For 2027
The line chart displays the monthly closing prices of Par Drugs and with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Par Drugs and shares in 2027, see the table below.
Par Drugs and Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 103.65 (+10.97%) | Volatility: ATR T1 |
| 2027 Target 2 | 95.53 (+2.28%) | Trend: SMA200 |
| 2027 Target 1 | 95.04 (+1.75%) | Trend: Supertrend Resistance |
| Current Price | 93.40 | Par Drugs and's share price as of 15 Jun 2026 |
| Stop Loss 1 | 89.74 (-3.92%) | Trend: SMA50 |
| Stop Loss 2 | 88.39 (-5.37%) | Trend: EMA9 |
| Stop Loss 3 | 83.15 (-10.98%) | Volatility: ATR S1 |
Long-Term Technical Outlook
52-Week Range Analysis: Par Drugs and is currently trading at 34.6% of its 52-week range (₹78.05 - ₹122.43).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -11.42% | 3-year: -57.49% | 5-year: +26.63%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Par Drugs and Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹93.40 | ||
| 2026 | ₹93.33 | -0.07494646680943% | ₹94.73 |
| 2027 | ₹112.54 | +20.582877959927% | ₹114.23 |
| 2028 | ₹139.97 | +24.373556068953% | ₹142.07 |
| 2029 | ₹159.04 | +13.624348074587% | ₹161.43 |
| 2030 | ₹178.24 | +12.072434607646% | ₹180.91 |
| 2031 | ₹196.59 | +10.295107719928% | ₹199.54 |
| 2032 | ₹221.16 | +12.498092476728% | ₹224.48 |
| 2033 | ₹283.93 | +28.382166757099% | ₹288.19 |
| 2034 | ₹318.08 | +12.027612439686% | ₹322.85 |
| 2035 | ₹352.93 | +10.956363179074% | ₹358.22 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Par Drugs and Brief Company Overview
Par Drugs and Chemicals Limited: A Reputable Pharma Player Established in 1982, Par Drugs and Chemicals Limited is a well-respected Indian company in the pharmaceutical industry. Headquartered in Vadodara, the company specializes in developing, manufacturing, and...
distributing a wide range of active pharmaceutical ingredients. Par Drugs and Chemicals Limited has a strong reputation for its commitment to quality and innovation. Diverse Product Offerings: Magnesium salts Dried aluminum hydroxide gel Sodium aluminum silicate Precipitated silica Magnesium silicate Colloidal silicon dioxide Sucralfate USP Amorphous and blended products The company's diverse product portfolio caters to various therapeutic areas and meets the needs of pharmaceutical manufacturers globally.Par Drugs and Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 287.62 Crore | Market valuation of Par Drugs and's shares. |
| Revenue (TTM) | 97.31 Crore | Total revenue generated by Par Drugs and over the past twelve months. |
| Net Income (TTM) | +14.22 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 18.18% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 14.62% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+4.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+83.2% | Change in earnings compared to the same quarter last year. |
| Total Cash | 29.85 Crore | Total amount of liquid funds available to Par Drugs and. |
| Beta | 0.25 | Beta is less than 1 indicating that the Par Drugs and's price is less volatile than the market. |
Is Par Drugs and A Good Buy For Long Term?
Par Drugs, a small-cap stock, exhibits impressive financial performance with a significant change in earnings (83.2%) and a healthy profit margin (14.62%). Its recent quarterly returns are promising, and long-term returns have been substantial (540.41% in 3 years). With a strong cash balance and consistent revenue growth, Par Drugs presents itself as a potentially lucrative investment for long-term growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
